Literature DB >> 32637914

Screening for Fabry Disease in Patients With Juvenile Systemic Lupus Erythematosus.

Ertugrul Kiykim1, Sezgin Şahİn2, Tanyel ZubarioĞlu1, Kenan Barut2, Amra Adrovic2, Mehmet Şerif Cansever3, Ayşe Çiğdem AktuĞlu Zeybek1, Özgür KasapÇopur1.   

Abstract

OBJECTIVES: This study aims to determine the prevalence of Fabry disease (FD) among patients with juvenile systemic lupus erythematosus (SLE). PATIENTS AND METHODS: This cross-sectional study included 76 juvenile SLE patients (12 males; 64 females; mean age 16±3.3 years; range, 8 to 23.5 years) who were diagnosed according to 1997 update of the 1982 American College of Rheumatology revised criteria for classification of SLE. Since the majority of patients were female, alpha-galactosidase A gene was investigated for mutations resulting in FD. Lysosomal accumulation of globotriaosylsphingosine (lyso-Gb3) was further evaluated in mutation positive subjects by using dried blood spot testing.
RESULTS: Alpha-galactosidase A gene screening did not yield any positive mutation in our 74 subjects. However, a heterozygous p.D313Y mutation was found in two females. These subjects were further investigated for lyso-Gb3 levels in dried blood spot samples and the levels of lyso-Gb3 being normal lead to exclusion of FD in these two patients.
CONCLUSION: We do not suggest routine screening of FD in patients with juvenile SLE; however, prospective studies with larger sample sizes are needed for further analysis.
Copyright © 2020, Turkish League Against Rheumatism.

Entities:  

Year:  2020        PMID: 32637914      PMCID: PMC7322306          DOI: 10.5606/ArchRheumatol.2020.7135

Source DB:  PubMed          Journal:  Arch Rheumatol        ISSN: 2148-5046            Impact factor:   1.472


  34 in total

1.  IgA nephropathy in two adolescent sisters heterozygous for Fabry disease.

Authors:  Catharina Whybra; Andreas Schwarting; Jörg Kriegsmann; Andreas Gal; Eugen Mengel; Christoph Kampmann; Frank Baehner; Ellen Schaefer; Michael Beck
Journal:  Pediatr Nephrol       Date:  2006-07-13       Impact factor: 3.714

2.  Chloroquine Toxicity Misdiagnosed as Fabry Disease Associated with Systemic Lupus Erythematosus and Hashimoto Thyroiditis.

Authors:  Marta Navratil; Irena Ivković Jureković
Journal:  J Rheumatol       Date:  2017-12       Impact factor: 4.666

3.  European evidence-based recommendations for the diagnosis and treatment of childhood-onset lupus nephritis: the SHARE initiative.

Authors:  Noortje Groot; Nienke de Graeff; Stephen D Marks; Paul Brogan; Tadej Avcin; Brigitte Bader-Meunier; Pavla Dolezalova; Brian M Feldman; Isabelle Kone-Paut; Pekka Lahdenne; Liza McCann; Seza Özen; Clarissa A Pilkington; Angelo Ravelli; Annet van Royen-Kerkhof; Yosef Uziel; Bas J Vastert; Nico M Wulffraat; Michael W Beresford; Sylvia Kamphuis
Journal:  Ann Rheum Dis       Date:  2017-09-06       Impact factor: 19.103

4.  How well does urinary lyso-Gb3 function as a biomarker in Fabry disease?

Authors:  Christiane Auray-Blais; Aimé Ntwari; Joe T R Clarke; David G Warnock; João Paulo Oliveira; Sarah P Young; David S Millington; Daniel G Bichet; Sandra Sirrs; Michael L West; Robin Casey; Wuh-Liang Hwu; Joan M Keutzer; X Kate Zhang; René Gagnon
Journal:  Clin Chim Acta       Date:  2010-08-14       Impact factor: 3.786

Review 5.  Alterations in membrane trafficking and pathophysiological implications in lysosomal storage disorders.

Authors:  Eva-Maria Kuech; Graham Brogden; Hassan Y Naim
Journal:  Biochimie       Date:  2016-09-21       Impact factor: 4.079

Review 6.  Biochemical basis of Fabry disease with emphasis on mitochondrial function and protein trafficking.

Authors:  A M Das; H Y Naim
Journal:  Adv Clin Chem       Date:  2009       Impact factor: 5.394

7.  [A case of Fabry's disease associated with lupus nephritis].

Authors:  K Majima; T Ishizaki; T Inoue; Y Hori; J Egami; A Oohara; H Nishida; Y Miyake; S Matsumoto; E Kinoshita
Journal:  Nihon Jinzo Gakkai Shi       Date:  1992-11

8.  High incidence of autoantibodies in Fabry disease patients.

Authors:  P Martinez; M Aggio; P Rozenfeld
Journal:  J Inherit Metab Dis       Date:  2007-04-24       Impact factor: 4.982

9.  Characterization of Fabry disease in 352 pediatric patients in the Fabry Registry.

Authors:  Robert J Hopkin; John Bissler; Maryam Banikazemi; Lorne Clarke; Christine M Eng; Dominique P Germain; Roberta Lemay; Anna Tylki-Szymanska; William R Wilcox
Journal:  Pediatr Res       Date:  2008-11       Impact factor: 3.756

10.  Fabry disease defined: baseline clinical manifestations of 366 patients in the Fabry Outcome Survey.

Authors:  A Mehta; R Ricci; U Widmer; F Dehout; A Garcia de Lorenzo; C Kampmann; A Linhart; G Sunder-Plassmann; M Ries; M Beck
Journal:  Eur J Clin Invest       Date:  2004-03       Impact factor: 4.686

View more
  1 in total

Review 1.  Expert opinion on the recognition, diagnosis and management of children and adults with Fabry disease: a multidisciplinary Turkey perspective.

Authors:  Fatih Ezgu; Erkan Alpsoy; Zerrin Bicik Bahcebasi; Ozgur Kasapcopur; Melis Palamar; Huseyin Onay; Binnaz Handan Ozdemir; Mehmet Akif Topcuoglu; Omac Tufekcioglu
Journal:  Orphanet J Rare Dis       Date:  2022-03-02       Impact factor: 4.123

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.